Stock Track | Evotec SE Soars 5.39% Pre-Market on $5 Million Milestone Payment from Bristol Myers Squibb

Stock Track11-12

Evotec SE (EVO) stock surged 5.39% in pre-market trading on Wednesday, following an announcement of a significant milestone in its collaboration with Bristol Myers Squibb (BMY). The German biotech company revealed it had received a $5 million milestone payment, sparking investor enthusiasm.

The milestone payment was triggered by the U.S. Food and Drug Administration's (FDA) acceptance of an Investigational New Drug (IND) application for a product candidate developed under the companies' protein degradation partnership. Specifically, the drug candidate is described as a cereblon E3 ligase modulator, showcasing Evotec's progress in this cutting-edge area of drug development.

This development marks a significant step forward in Evotec's collaboration with Bristol Myers Squibb and underscores the company's growing potential in the competitive biotech landscape. Looking ahead, Evotec announced that a phase 1 clinical trial for this promising drug candidate is expected to commence next year, further bolstering investor confidence in the company's pipeline and research capabilities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183092945?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 22:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183092945","market":"hk","top_or_hot":-1,"title":"Stock Track | Evotec SE Soars 5.39% Pre-Market on $5 Million Milestone Payment from Bristol Myers Squibb","media":"Stock Track","content":"<p>Evotec SE (EVO) stock surged 5.39% in pre-market trading on Wednesday, following an announcement of a significant milestone in its collaboration with Bristol Myers Squibb (BMY). The German biotech company revealed it had received a $5 million milestone payment, sparking investor enthusiasm.</p>\n\n<p>The milestone payment was triggered by the U.S. Food and Drug Administration's (FDA) acceptance of an Investigational New Drug (IND) application for a product candidate developed under the companies' protein degradation partnership. Specifically, the drug candidate is described as a cereblon E3 ligase modulator, showcasing Evotec's progress in this cutting-edge area of drug development.</p>\n\n<p>This development marks a significant step forward in Evotec's collaboration with Bristol Myers Squibb and underscores the company's growing potential in the competitive biotech landscape. Looking ahead, Evotec announced that a phase 1 clinical trial for this promising drug candidate is expected to commence next year, further bolstering investor confidence in the company's pipeline and research capabilities.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Evotec SE Soars 5.39% Pre-Market on $5 Million Milestone Payment from Bristol Myers Squibb</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Evotec SE Soars 5.39% Pre-Market on $5 Million Milestone Payment from Bristol Myers Squibb\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 22:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Evotec SE (EVO) stock surged 5.39% in pre-market trading on Wednesday, following an announcement of a significant milestone in its collaboration with Bristol Myers Squibb (BMY). The German biotech company revealed it had received a $5 million milestone payment, sparking investor enthusiasm.</p>\n\n<p>The milestone payment was triggered by the U.S. Food and Drug Administration's (FDA) acceptance of an Investigational New Drug (IND) application for a product candidate developed under the companies' protein degradation partnership. Specifically, the drug candidate is described as a cereblon E3 ligase modulator, showcasing Evotec's progress in this cutting-edge area of drug development.</p>\n\n<p>This development marks a significant step forward in Evotec's collaboration with Bristol Myers Squibb and underscores the company's growing potential in the competitive biotech landscape. Looking ahead, Evotec announced that a phase 1 clinical trial for this promising drug candidate is expected to commence next year, further bolstering investor confidence in the company's pipeline and research capabilities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"EVO","symbol_name":"Evotec SE","start_time":0,"source_url":"","article_id":"1183092945","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183092945","pubTimestamp":1762959020,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Evotec SE (EVO) stock surged 5.39% in pre-market trading on Wednesday, following an announcement of a significant milestone in its collaboration with Bristol Myers Squibb (BMY). The German biotech...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"EVO":"Evotec SE"},"translate_title":"股票追踪|Evotec SE盘前飙升5.39%，获百时美施贵宝500万美元里程碑付款","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EVO":1},"content_text":"Evotec SE (EVO) stock surged 5.39% in pre-market trading on Wednesday, following an announcement of a significant milestone in its collaboration with Bristol Myers Squibb (BMY). The German biotech company revealed it had received a $5 million milestone payment, sparking investor enthusiasm.\nThe milestone payment was triggered by the U.S. Food and Drug Administration's (FDA) acceptance of an Investigational New Drug (IND) application for a product candidate developed under the companies' protein degradation partnership. Specifically, the drug candidate is described as a cereblon E3 ligase modulator, showcasing Evotec's progress in this cutting-edge area of drug development.\nThis development marks a significant step forward in Evotec's collaboration with Bristol Myers Squibb and underscores the company's growing potential in the competitive biotech landscape. Looking ahead, Evotec announced that a phase 1 clinical trial for this promising drug candidate is expected to commence next year, further bolstering investor confidence in the company's pipeline and research capabilities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183092945","isCrawlerRequest":true}